Parathyroid hormone (PTH), acting through the PTH receptor (PTHR1), expressed in bone and kidney, plays a vital role in maintaining proper blood levels of calcium and phosphate, and also contributes to the regulation of bone growth and remodeling. PTHrP, acting through the same PTHR1, regulates the development of the skeleton and other tissues. Drugs that target the PTHR1 are of interest because they could potentially be used to treat human diseases, such as osteoporosis and hypoparathyroidism (HPT). Yet PTH(1-34) is the only FDA-approved PTH-based therapy. It is thus used to treat osteoporosis, and, while effective, must be injected once a day. The proposed studies will define the molecular mechanisms by which PTH ligands bind to and activate the PTHR1. They will generate new types of PTH analogs, including signaling selective analogs and novel long-acting ligands that are structurally more stable or have adducts that impair renal clearance, and will assess these analogs for binding to the PTHR1 in vitro, and for actions in animals. Also explored will be new non-peptidic, small-molecule ligands for the PTHR1. Selected ligands will be evaluated in a mouse model of HPT (PTH-null mice) for their capacity to normalize blood calcium. New long-acting PTH analogs will also be tested for their capacities to stimulate bone formation and improve strength when injected into mice at low-frequency intervals, such as once-weekly, and in a dual-therapy mode with the bone-resorption inhibitor, OPG-FC.

Public Health Relevance

The proposed studies will lead to a better understanding of how PTH ligands bind to and activate the PTHR1. They will also provide clues for. how to develop and utilize new PTH ligand analogs for more effective treatment of diseases such as osteoporosis and hypoparathyroidism.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZDK1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts General Hospital
United States
Zip Code
Bi, Ruiye; Fan, Yi; Lauter, Kelly et al. (2016) Diphtheria Toxin- and GFP-Based Mouse Models of Acquired Hypoparathyroidism and Treatment With a Long-Acting Parathyroid Hormone Analog. J Bone Miner Res 31:975-84
Stevenson, Hilary P; Lin, Guowu; Barnes, Christopher O et al. (2016) Transmission electron microscopy for the evaluation and optimization of crystal growth. Acta Crystallogr D Struct Biol 72:603-15
Ono, Noriaki; Kronenberg, Henry M (2016) Bone repair and stem cells. Curr Opin Genet Dev 40:103-107
Kim, Sang Wan; Lu, Yanhui; Williams, Elizabeth A et al. (2016) Sclerostin Antibody Administration Converts Bone Lining Cells into Active Osteoblasts. J Bone Miner Res :
Wein, Marc N; Liang, Yanke; Goransson, Olga et al. (2016) SIKs control osteocyte responses to parathyroid hormone. Nat Commun 7:13176
Eda, Homare; Santo, Loredana; Wein, Marc N et al. (2016) Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease. J Bone Miner Res 31:1225-34
Sinha, Partha; Aarnisalo, Piia; Chubb, Rhiannon et al. (2016) Loss of Gsα in the Postnatal Skeleton Leads to Low Bone Mass and a Blunted Response to Anabolic Parathyroid Hormone Therapy. J Biol Chem 291:1631-42
Tenhola, Sirpa; Voutilainen, Raimo; Reyes, Monica et al. (2016) Impaired growth and intracranial calcifications in autosomal dominant hypocalcemia caused by a GNA11 mutation. Eur J Endocrinol 175:211-8
Cheloha, Ross W; Watanabe, Tomoyuki; Dean, Thomas et al. (2016) Backbone Modification of a Parathyroid Hormone Receptor-1 Antagonist/Inverse Agonist. ACS Chem Biol 11:2752-2762
Hattersley, Gary; Dean, Thomas; Corbin, Braden A et al. (2016) Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling. Endocrinology 157:141-9

Showing the most recent 10 out of 195 publications